1. Mann RD, Andrews EB (2007) Introduction. In: Mann RD, Andrews EB (eds) Pharmacovigilance, 2nd edn. John Wiley & Sons, Chichester, pp 1–12
2. Bührlen B, Reiß T, Beckmann C, et al. on behalf of Fraunhofer Institute for Systems and Innovation Research (2006) Assessment of the European Community System of Pharmacovigilance. Stuttgart: Fraunhofer IRB, 2006 sample. Available at: http://www.cbg-meb.nl/NR/rdonlyres/497C7834-7B4F-4D03-BE31-226F96234696/0/20060317rappfraunhofer.pdf . Accessed 2 Dec 2010
3. Nelson RC, Palsulich B, Gogolak V (2002) Good pharmacovigilance practices: technology enabled. Drug Saf 25(6):407–14
4. van Puijenbroek EP, van Grootheest K, Diemont WL, et al (2001) Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol 52(5):579-86
5. EudraVigilance Expert Working Group (2010) Note for guidance—EudraVigilance Human—Processing of safety messages and individual case safety reports (ICSRs) EMA/H/20665/04/Final Rev. 2, 15 October, 2010. European Medicines Agency, London